Compare Merck & Co., Inc. (MRK) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while iShares 20 Plus Year Treasury Bond ETF trades at $81.66. The key difference: Merck & Co., Inc. pays a 2.29% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| MRK | TLT | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | — |
52-Week High | $156.43 | $92.06 |
52-Week Low | $77.60 | $81.35 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.2 with minimal daily change. Technical signals are bearish, with moving averages indicating selling pressure and oscillators neutral. Recent Treasury buyback announcements and rising global bond yields create a volatile backdrop. The ETF continues its dividend distributions, with recent payments around $0.32 per share.
Outlook remains cautious amid rising interest rate expectations and inflation concerns. Investment opportunity exists for long-term income seekers, but risks include further yield increases and potential large-scale Treasury selling by institutional investors like Norway's sovereign fund.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
